Dianthus Therapeutics (DNTH) Competitors $20.00 +0.79 (+4.11%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DNTH vs. ZLAB, BHC, RXRX, CPRX, GMTX, TWST, HCM, EWTX, AMRX, and KYMRShould you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Zai Lab (ZLAB), Bausch Health Companies (BHC), Recursion Pharmaceuticals (RXRX), Catalyst Pharmaceuticals (CPRX), Gemini Therapeutics (GMTX), Twist Bioscience (TWST), HUTCHMED (HCM), Edgewise Therapeutics (EWTX), Amneal Pharmaceuticals (AMRX), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry. Dianthus Therapeutics vs. Zai Lab Bausch Health Companies Recursion Pharmaceuticals Catalyst Pharmaceuticals Gemini Therapeutics Twist Bioscience HUTCHMED Edgewise Therapeutics Amneal Pharmaceuticals Kymera Therapeutics Zai Lab (NASDAQ:ZLAB) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, community ranking, risk, profitability, media sentiment, analyst recommendations and institutional ownership. Is ZLAB or DNTH more profitable? Zai Lab has a net margin of -76.14% compared to Dianthus Therapeutics' net margin of -1,250.32%. Dianthus Therapeutics' return on equity of -21.68% beat Zai Lab's return on equity.Company Net Margins Return on Equity Return on Assets Zai Lab-76.14% -36.97% -27.10% Dianthus Therapeutics -1,250.32%-21.68%-20.88% Does the MarketBeat Community believe in ZLAB or DNTH? Zai Lab received 203 more outperform votes than Dianthus Therapeutics when rated by MarketBeat users. However, 95.83% of users gave Dianthus Therapeutics an outperform vote while only 64.20% of users gave Zai Lab an outperform vote. CompanyUnderperformOutperformZai LabOutperform Votes22664.20% Underperform Votes12635.80% Dianthus TherapeuticsOutperform Votes2395.83% Underperform Votes14.17% Does the media favor ZLAB or DNTH? In the previous week, Zai Lab had 6 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 10 mentions for Zai Lab and 4 mentions for Dianthus Therapeutics. Zai Lab's average media sentiment score of 0.62 beat Dianthus Therapeutics' score of 0.45 indicating that Zai Lab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 2 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of ZLAB or DNTH? 41.7% of Zai Lab shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 13.9% of Zai Lab shares are held by insiders. Comparatively, 16.6% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation and earnings, ZLAB or DNTH? Dianthus Therapeutics has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZai Lab$266.72M10.69-$334.62M-$2.77-9.40Dianthus Therapeutics$2.83M209.19-$43.56M-$2.50-8.00 Do analysts rate ZLAB or DNTH? Zai Lab currently has a consensus target price of $55.00, suggesting a potential upside of 111.13%. Dianthus Therapeutics has a consensus target price of $46.43, suggesting a potential upside of 132.14%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dianthus Therapeutics is more favorable than Zai Lab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zai Lab 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20 Which has more risk & volatility, ZLAB or DNTH? Zai Lab has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Dianthus Therapeutics has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500. SummaryDianthus Therapeutics beats Zai Lab on 14 of the 19 factors compared between the two stocks. Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNTH vs. The Competition Export to ExcelMetricDianthus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$592M$6.16B$5.18B$9.11BDividend YieldN/A2.93%5.35%4.02%P/E Ratio-8.009.9189.8717.36Price / Sales209.19181.261,200.7062.75Price / CashN/A61.4443.8235.97Price / Book1.756.055.324.79Net Income-$43.56M$154.90M$122.69M$225.00M7 Day Performance-13.19%-0.31%0.58%2.62%1 Month Performance-15.97%0.43%2.51%3.81%1 Year Performance67.36%3.08%25.77%20.10% Dianthus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNTHDianthus Therapeutics1.6525 of 5 stars$20.00+4.1%$46.43+132.1%+67.4%$592M$2.83M-8.0080Short Interest ↑ZLABZai Lab2.7093 of 5 stars$25.00-1.2%$55.00+120.0%+11.1%$2.74B$355.75M-9.032,175BHCBausch Health Companies3.4589 of 5 stars$7.46-5.3%$7.75+3.9%-8.7%$2.70B$9.47B-15.5420,270Short Interest ↓Positive NewsRXRXRecursion Pharmaceuticals2.4464 of 5 stars$6.72-2.3%$8.75+30.2%-32.2%$2.63B$64.60M-4.39400Gap UpCPRXCatalyst Pharmaceuticals4.7257 of 5 stars$21.97+0.2%$32.86+49.6%+56.5%$2.62B$460.48M18.6280Short Interest ↑GMTXGemini TherapeuticsN/A$59.25-5.3%N/A-6.2%$2.57BN/A-59.2530High Trading VolumeTWSTTwist Bioscience2.8354 of 5 stars$43.15-1.0%$51.90+20.3%+41.5%$2.56B$312.97M-11.99990Gap UpHCMHUTCHMED2.5819 of 5 stars$14.55-3.2%$19.00+30.6%-0.5%$2.54B$420.26M0.001,988Positive NewsGap DownEWTXEdgewise Therapeutics2.1255 of 5 stars$25.40+5.2%$43.17+69.9%+101.4%$2.41BN/A-16.9360Short Interest ↑Positive NewsGap DownAMRXAmneal Pharmaceuticals3.5063 of 5 stars$7.75-2.8%$10.00+29.0%+53.0%$2.40B$2.68B-11.407,700Short Interest ↓KYMRKymera Therapeutics2.9199 of 5 stars$36.95-3.2%$55.38+49.9%+47.7%$2.39B$87.56M-15.79170 Related Companies and Tools Related Companies Zai Lab Alternatives Bausch Health Companies Alternatives Recursion Pharmaceuticals Alternatives Catalyst Pharmaceuticals Alternatives Gemini Therapeutics Alternatives Twist Bioscience Alternatives HUTCHMED Alternatives Edgewise Therapeutics Alternatives Amneal Pharmaceuticals Alternatives Kymera Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DNTH) was last updated on 1/20/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNTH Stock Alerts